The treatment success rate for patients with multidrug-resistant tuberculosis in Germany is forecasted to grow slowly from 57% in 2024 to 58% by 2028. In 2023, the success rate stood at 56%, indicating a modest improvement over the analyzed period. The compound annual growth rate (CAGR) reflects a minimal increase in success rates.

Future trends to watch for:

Enhanced treatment protocols and drug advancements could accelerate success rates.
Public health initiatives and screening programs may impact future rates positively.
Monitoring emerging resistant strains is crucial for strategic planning.